Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Delayed
Japan Exchange
01:00:23 2026-08-26 am EDT
|
5-day change | 1st Jan Change | ||
| 5,879.00 JPY | +1.14% |
|
+1.92% | +21.61% |
| Aug. 24 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
| Aug. 24 | Takeda's Orzeryful Approved in Japan as First Treatment Targeting Narcolepsy Type 1 | MT |
| Market Cap | 9,282B 58.27B 49.93B 46.79B 42.74B 80.66B 5,555B 81.45B 552B 215B 2,803B 219B 214B | P/E 2027 * |
46.7x | P/E 2028 * | 29.9x |
|---|---|---|---|---|---|
| Enterprise Value | 13,184B 82.77B 70.93B 66.46B 60.71B 115B 7,891B 116B 784B 305B 3,981B 311B 304B | EV / Sales 2027 * |
2.81x | EV / Sales 2028 * | 2.72x |
| Free-Float |
99.26% | Yield 2027 * |
3.52% | Yield 2028 * | 3.58% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +1.08% | ||
| 1 week | +1.85% | ||
| Current month | +6.58% | ||
| 1 month | +1.85% | ||
| 3 months | +16.13% | ||
| 6 months | +2.53% | ||
| Current year | +21.53% |
| 1 week | 5,729 |  | 5,906 |
| 1 month | 5,225 | | 5,906 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2024-12-31 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 2024-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 2022-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 2015-05-31 |
Steven Gillis
BRD | Director/Board Member | 73 | 2018-12-31 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 2024-05-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/19/26 | Sell | Chief Technology Officer | -19,651 | 0.0012% | ||
| 8/18/26 | Sell | Head of Human Resources | -12,980 | 0.0008% | ||
| 8/11/26 | Sell | Pres., Global Supply & Quality | -20,363 | 0.0013% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.10% | +1.85% | +33.48% | +31.40% | 58.27B | |
| -1.06% | +0.65% | +77.42% | +122.82% | 1,100B | |
| +0.53% | +0.75% | +53.10% | +64.29% | 658B | |
| +0.48% | +2.65% | +28.06% | +81.19% | 470B | |
| +0.92% | +3.57% | +43.82% | +44.21% | 372B | |
| +1.25% | +2.21% | +26.77% | +43.05% | 304B | |
| +3.02% | +5.68% | +4.24% | +17.04% | 264B | |
| -0.36% | +3.99% | +53.31% | +72.49% | 239B | |
| +2.86% | +3.86% | -16.20% | -51.83% | 213B | |
| +1.38% | +3.72% | +30.33% | +93.56% | 184B | |
| Average | +1.01% | +2.95% | +33.43% | +51.82% | 386.12B | |
| Weighted average by Cap. | +0.46% | +2.11% | +45.49% | +71.20% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,687B 29.42B 25.21B 23.63B 21.58B 40.73B 2,805B 41.13B 279B 108B 1,415B 110B 108B | 4,766B 29.92B 25.64B 24.03B 21.95B 41.42B 2,853B 41.82B 283B 110B 1,439B 112B 110B |
| Net income | 194B 1.22B 1.04B 977M 892M 1.68B 116B 1.7B 11.52B 4.49B 58.52B 4.57B 4.47B | 318B 1.99B 1.71B 1.6B 1.46B 2.76B 190B 2.79B 18.88B 7.35B 95.88B 7.48B 7.32B |
| Net Debt | 3,902B 24.5B 20.99B 19.67B 17.97B 33.91B 2,336B 34.24B 232B 90.32B 1,178B 91.99B 89.98B | 3,701B 23.24B 19.91B 18.66B 17.04B 32.16B 2,215B 32.48B 220B 85.67B 1,118B 87.25B 85.34B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-26 | ¥5,879.00 | +1.14% | 1,796,500 |
| 26-08-25 | ¥5,813.00 | +0.28% | 3,025,100 |
| 26-08-24 | ¥5,797.00 | +0.57% | 2,568,100 |
| 26-08-21 | ¥5,764.00 | -1.05% | 3,177,000 |
| 26-08-20 | ¥5,825.00 | +0.97% | 5,268,300 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
